en.Wedoany.com Reported - Memorial Sloan Kettering Cancer Center (MSK) and Sophia Genetics, an AI health technology company, have signed a memorandum of understanding, announcing a collaboration on a precision oncology project.

In a joint announcement on June 6, the two institutions stated that the goal of this partnership is to leverage MSK's clinical data and Sophia Genetics' AI platform to create a precision medicine center for cancer patients worldwide. According to Sophia Genetics, its precision medicine platform has analyzed over 2.5 million cases since 2014. Meanwhile, MSK has sequenced more than 150,000 tumor samples using its internal next-generation sequencing platform since 2014.

Michael Frank, Director of Digital Health Business Development at MSK, said in a statement that this collaboration represents the future of applied precision oncology, combining clinical expertise with cutting-edge AI and robotics to potentially transform cancer treatment on a large scale. By integrating MSK's deep clinical assets with Sophia Genetics' digital platform, the two parties seek to create a new paradigm that delivers personalized insights to patients.

Details surrounding this strategic initiative have not yet been finalized, but the two institutions envision Sophia serving as the center's AI and analytics platform, with MSK providing clinical and scientific leadership as well as clinical data. The two organizations have previously collaborated on diagnostic innovation.

Ross Muken, President of Sophia Genetics, stated in a release that the company's partnership with MSK has always focused on expanding the reach of MSK's clinical intelligence, calling the upcoming collaboration the most ambitious expression of this mission to date. Muken noted that over the past few years, they have built SOPHiA DDM into a foundational AI and analytics layer for precision medicine, helping institutions worldwide unlock the value of their clinical data. By combining MSK's clinical leadership and deep clinical data with Sophia Genetics' AI platform and global infrastructure, the precision medicine center under discussion will help advance precision oncology into the multimodal era and bring the benefits of MSK's precision oncology to patients.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com